Retatrutide is currently considered an investigational compound and is not yet widely approved for routine clinical use
Future prospective, randomized studies with larger cohorts, longer follow-up periods, structured comorbidity assessment, and objective monitoring of lifestyle adherence are warranted to confirm and extend these findings
On 7 April, the FDA published several warning letters, including a batch to companies that the agency said are marketing GLP-1 products, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) products, and triple agonist (GLP-1/GIP/glucagon) products without regulatory approval
Practical Tips to Maximize Results Getting the most out of your glutathione supplement isnt just about the dose, its about how you support your body to absorb and use it effectively
More than 3,700 lawsuits relating to Ozempic and other GLP-1 weight loss drugs are consolidated into multidistrict litigation (MDL) in Pennsylvania federal court